octylonium has been researched along with regorafenib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, Y; Meng, Q; Shi, L; Wang, H; Xu, Z; Zhang, N; Zhou, H; Zhu, M | 1 |
1 other study(ies) available for octylonium and regorafenib
| Article | Year |
|---|---|
Otilonium Bromide acts as a selective USP28 inhibitor and exhibits cytotoxic activity against multiple human cancer cell lines.
Topics: Antineoplastic Agents; Cell Line; Colorectal Neoplasms; Humans; Quaternary Ammonium Compounds; Ubiquitin Thiolesterase | 2023 |